{
  "model": "gemini-3-flash-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/gemini-3-flash-preview-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 142474,
  "agentCostUsd": 0,
  "graderCostUsd": 0.0203945,
  "totalCostUsd": 0.0203945,
  "agentUsage": {
    "promptTokens": 58746,
    "cachedTokens": 26608,
    "responseTokens": 2906,
    "thinkingTokens": 8270,
    "totalTokens": 69922
  },
  "graderUsage": {
    "promptTokens": 3846,
    "cachedTokens": 0,
    "responseTokens": 375,
    "thinkingTokens": 601,
    "totalTokens": 4822
  },
  "totalUsage": {
    "promptTokens": 62592,
    "cachedTokens": 26608,
    "responseTokens": 3281,
    "thinkingTokens": 8871,
    "totalTokens": 74744
  },
  "modelVersions": [
    "gemini-3-flash-preview"
  ],
  "agentFinalText": "Checklist of written output files:\n- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"78 tumor-bearing mice pooled across repeat experiments receiving combination therapy of intratumoral mRNA vaccine and anti-PD-L1.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"84 tumor-bearing mice pooled across matched controls receiving vaccine only, ICI only, and vehicle treatments.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"A retrospective cohort of 130 metastatic patients total receiving immune checkpoint inhibitor (ICI) treatment.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subgroup of 43 patients who received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subgroup of 87 patients who were unvaccinated for SARS-CoV-2 prior to ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}\n"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Interferon-associated antigen processing and presentation pathways increase following vaccination.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Combined intervention improves tumor control in mouse models.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with better outcomes in retrospective human cohorts.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"aligns with better outcomes in the retrospective human cohort\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA Vaccines May Prime Tumors for Better Response to Immune Therapy\",\n  \"plain_language_summary\": \"This study investigates a novel strategy to enhance the effectiveness of cancer immunotherapy. Some tumors are resistant to immune checkpoint inhibitors (ICIs) because they do not adequately present antigens to the immune system. The researchers demonstrated that delivering an mRNA vaccine directly into the tumor induces a state rich in type I interferons. This inflammatory environment promotes broader antigen presentation on MHC-I molecules, making the tumor more visible to the immune system's T cells. In animal models, combining the mRNA vaccine with anti-PD-L1 therapy significantly improved tumor control compared to single-agent treatments. Additionally, a retrospective analysis of 130 human patients with metastatic cancer suggests that those who had previously received a SARS-CoV-2 mRNA vaccine experienced better survival outcomes when treated with ICIs. These findings provide a biological rationale for using mRNA vaccines to sensitize tumors to checkpoint blockade, though prospective clinical trials are necessary to confirm these effects.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination can broaden the range of tumor antigens presented to the immune system.\",\n    \"Type I interferon signaling triggered by the vaccine increases PD-L1 expression, making tumors more targetable.\",\n    \"Retrospective data suggests a link between prior mRNA vaccination and improved survival in patients receiving immune therapy.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data is retrospective, meaning it looks back at past patients and can't prove a direct cause-and-effect relationship.\",\n    \"Patients in the study had different types of tumors and treatment histories, which could affect the results.\",\n    \"The timing of vaccination varied, and results from mouse models do not always translate perfectly to humans.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"mRNA Vaccine\",\n      \"definition\": \"A type of vaccine that uses messenger RNA to trigger an immune response without using the virus itself.\"\n    },\n    {\n      \"term\": \"Immune Checkpoint Inhibitors (ICIs)\",\n      \"definition\": \"Drugs that help the immune system recognize and attack cancer cells by 'releasing the brakes' on immune cells.\"\n    },\n    {\n      \"term\": \"Type I Interferon\",\n      \"definition\": \"Proteins released by cells in response to pathogens that help regulate the immune system's activity.\"\n    },\n    {\n      \"term\": \"MHC-I Peptidome\",\n      \"definition\": \"The collection of small protein fragments (peptides) displayed on the surface of cells for recognition by T cells.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Delivered or occurring directly inside a tumor.\"\n    }\n  ],\n  \"open_questions\": [\n    \"How long does the sensitization effect from mRNA vaccination last in humans?\",\n    \"Are certain tumor types more responsive to this combination therapy than others?\",\n    \"What is the optimal timing for mRNA vaccination relative to starting immune checkpoint inhibitor therapy?\"\n  ]\n}\n"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 24,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "list_directory"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-14T12:59:13.874Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-14T12:59:19.280Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-14T12:59:26.212Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-14T12:59:33.990Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-14T12:59:38.165Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-14T12:59:40.363Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-14T12:59:43.368Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-14T13:00:26.119Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-14T13:00:32.116Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-14T13:00:42.641Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-14T13:00:51.166Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "output",
        "timestamp": "2026-02-14T13:00:54.315Z"
      }
    ]
  },
  "grader": {
    "model": "gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 3,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [
        "Public summary overstates evidence by saying the combination “significantly improved tumor control” in animal models, but the report (e.g., L46) states improved tumor control without providing a statistical-significance claim or p-value for mouse efficacy. This introduces an unsupported inference about statistical testing.",
        "Claim audit C03 uses “Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x” (L33) as evidence for “improves tumor control in mouse models.” CD8 infiltration is a mechanistic/immune correlate, not direct tumor control/efficacy. While L46 supports improved tumor control, tying it to L33 risks misleading downstream users about what was actually measured.",
        "Study overview ‘major_limitations’ omits a reported caveat: “Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings” (L53). This is part of the stated threats to validity and is important for calibrated interpretation."
      ],
      "summary": "The JSON outputs largely mirror the report’s design (L13–L16), cohorts (L19–L23), and quantitative table values with correct line references (L28–L33). However, they contain key calibration/faithfulness problems: the public-facing summary adds an unsupported claim of statistical significance for mouse tumor control, and the claim audit improperly treats CD8 density (L33) as direct efficacy evidence. Additionally, the study_overview limitations miss an explicit caveat about model-specific mechan1"
    }
  }
}
